Podchaser Logo
Home
News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

Released Tuesday, 15th December 2020
Good episode? Give it some love!
News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

Tuesday, 15th December 2020
Good episode? Give it some love!
Rate Episode

News from ASH 2020:

  1. No benefit from tranexamic acid prophylaxis in blood cancers: https://bit.ly/2K3Mah1
  2. ‘Practice changing’: Ruxolitinib as second-line in chronic GVHD: https://bit.ly/3gT4kyg 
  3. Durable responses with anti-BCMA CAR T-cell for multiple myeloma: https://bit.ly/381f1ut
  4. Five-minute SC injection of daratumumab in RRMM: https://bit.ly/3gKuZgx

Email Blood & Cancer at [email protected]

 

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features